Introduction
A prognostic factor is defined as a biological or clinical variable that is associated with disease-free survival or overall survival in the absence of adjuvant systemic therapy. A predictive factor is any measurement associated with response or lack of response to a particular therapy (Laupacis et al., 1994) .
Identification of prognostic and/or predictive factors is important for several reasons (Schemper, 1993) . First, they allow establishing the probability of success or failure correlated to treatment. Moreover, they are valuable in designing clinical trials because they are used as eligibility criteria to ensure a relatively uniform study population. Finally, they may represent novel targets for therapy.
pRb, the protein product of the retinoblastoma gene (Rb), pRb2/p130 and p107 represent a family of closely related proteins that play critical roles in different functions of cellular life. Moreover, different mechanisms of inactivation of Rb family members have been demonstrated to play a role in the pathogenesis of human cancer (Masciullo et al., 2000) . In this overview, we will examine the clinical impact of deregulation of Rb family members in human cancer.
Breast cancer
The observation that the human Rb gene is inactivated in about 20% of breast carcinomas suggests that pRb may have an important role in the pathogenesis of this tumor (Fung and T'Ang, 1992) . The clinical importance of Rb function demands a reproducible Rb immunohistochemical assay to distinguish Rb þ from RbÀ tumor cells and many attempts have been made in this direction (Bianchi et al., 1994; Geradts et al., 1994) . The prognostic relevance of pRb alterations in breast cancer was disclosed by two independent studies. By immunohistochemistry (IHC), Pietilainen et al. (1995) found an abnormal pRb expression in 75 (36.6%) out of 205 cases of primary breast cancer. Abnormal pRb expression was defined as decreased or weak expression of pRB, and was significantly related to histopathological grade III (Po0.00004), ductal histology (P ¼ 0.0183), aneuploid DNA content (Po0.0002), nuclear pleomorphism (Po0.0001), high mitotic index (Po0.001), high S-phase fraction (P ¼ 0.004) and high morphometric nuclear factor values (Po0.01). In a series of 153 primary breast carcinomas (Ceccarelli et al., 1998) , pRb positively correlated with proliferative activity (as determined by Ki67), tumor size (with cases classified as T3 and T4 having the highest content of pRb), nuclear and histological grade (with G3 tumors having a higher degree of pRb labeling), estrogen/progesterone receptor content. These observations suggest that in those cases the protein behaves normally in regulating cell cycle.
Both these large studies failed to demonstrate a statistically significant correlation between pRb status and nodal involvement. To date, several studies have investigated the expression of pRb in human breast cancer to evaluate any correlation with a range of clinical and pathological parameters (Trudel et al., 1992; Bieche and Lidereau, 2000) . In all these studies, pRb decreased expression was related to histopathological grade III, negative estrogen receptor (ER) status and large tumor size, but no correlation with clinical outcome (Pinto et al., 2005) or nodal status has been reported. This can be explained by the fact that pRb loss enhances cell division rather than cell motility, which in breast cancer is mostly mediated by other factors such as ErbB-2 expression. Only two studies have identified a direct relationship between pRb status and nodal involvement (Sawan et al., 1992; Spandidos et al., 1992) ; whereas, Wakasugi et al. (1997) showed that the underphosphorylated (active) form of pRb was related to low risk of lymph node metastasis (Po0.01).
Although pRb expression in breast cancer has been extensively analysed, the role of pRb2/p130 in breast cancer is still under investigation. A study (MildeLangosch et al., 2001 ) on 68 mammary carcinomas revealed that reduced pRb2 expression was more frequent in lobular than in ductal carcinomas (P ¼ 0.033) and was not associated with age, clinical stage, nodal involvement, histological grading or Ki67 staining. Rb2/p130 expression significantly correlated with ER and progesterone receptor-B. Estrogen receptor-alpha and its ligand (17beta-estradiol) have been linked to mammary carcinogenesis and clinical outcome in breast cancer patients. In a recent study (Macaluso et al., 2003) , we demonstrated that pRb2/p130-containing complexes bind to the ER-alpha promoter and could be involved in the transcriptional regulation of the ERalpha gene by altering chromatin structure and DNA methylation pattern. Studies are ongoing in our laboratory to confirm this hypothesis.
Ovarian cancer
Although loss of heterozygosis (LOH) at the site of the Rb gene (13q14) has been reported as a frequent event in ovarian carcinomas (Liu et al., 1994) , data concerning the corresponding loss of pRb are still controversial (Dodson et al., 1994; Kim et al., 1994) . It is conceivable that pRb/p105 is not always the target of allelic loss at 13q14 and that other 13q genes could be involved in malignant transformation. Dong et al. (1997) have investigated the prognostic significance of pRb status in a series of 168 specimens, including benign, low malignant potential (LMP) and malignant ovarian tumors. Forty-one percent of the benign, 50% of the LMP and 71% of the malignant tumors showed high pRb expression. Protein accumulation increased progressively with poorer differentiation (P ¼ 0.02) and there was a trend for high pRb expression to be associated with advanced stage of disease (P ¼ 0.07). Except for stage I tumors, pRb levels were not correlated with patients survival. Additionally, MildeLangosch et al. (2003) found a paradoxical correlation between higher pRb expression and shorter survival. It is therefore possible that pRb expression could play a role in controlling early tumorigenesis, whereas in later stages, the tumor is independent from pRb.
Recent studies have shown that defects in the 'Rb/ cyclin D1/p16 pathway' (also known as G1 pathway) may play a major role in the development of ovarian cancer (Bartkova et al., 1996) . In many solid tumors, there is a reciprocal correlation between genetic alterations of single members of this pathway (Kusume et al., 1999) , indicating that different molecular alterations of this pathway can lead to the same result: abnormal E2F expression. The simultaneous analysis of pRb, p16, cyclin D1 and CDK4 status in a series of 59 epithelial ovarian cancer specimens from patients who underwent surgery and platinum-based chemotherapy did not reveal any association with clinicopathological parameters or prognosis. However, patients with normal G1 pathway tended to achieve a higher complete response rate to chemotherapy, compared with patients with abnormal G1 pathway (P ¼ 0.1001). Abnormal G1 pathway was an independent prognostic factor for overall survival (P ¼ 0.0213), as recently confirmed in another study (Hashiguchi et al., 2004) .
A role for pRb2/p130 in the pathogenesis of ovarian cancer is suggested by the frequent LOH (38-67% of cases) at chromosome 16q12.2 where the Rb2 gene maps. However, genetic alterations in the Rb2 gene (exon 19-22) are unlikely to be involved directly in the pathogenesis of sporadic ovarian cancer. Based on a previous study, demonstrating that pRb2 act as a tumor suppressor gene in vivo and in vitro in the SKOV3 ovarian cell line, we have recently showed in a large series of ovarian carcinomas that pRb2 expression decreases in 40% of cases and inversely correlates with tumor grade . Although pRb2 expression does not appear to affect prognosis, we demonstrated that its overexpression in ovarian cancer cells lacking p53 inhibits camptothecin-and doxorubicin-but not taxol-induced apoptosis .
Other gynecological malignancies
Several studies suggest that alteration of pRb expression is uncommon in endometrial carcinoma and when it does occur, it may represent a late event in carcinogenesis (Semczuk et al., 2000) . Loss of heterozygosis (LOH) at the Rb locus occurs in 10-18% of endometrial carcinomas; however, there is no significant correlation between Rb LOH and patient age, clinical stage, histological grade or myometrial invasion of the tumor.
The role of pRb2/p130 in endometrial carcinogenesis appears more relevant. We previously demonstrated by immunohistochemistry that reduced expression of pRb2/p130 is a strong independent predictor of poor outcome in endometrial cancer (Susini et al., 1998) . Specifically, decreased levels of pRb2/p130 in endometrial cancer cells were significantly associated with a decreased probability of remaining disease free after treatment (P ¼ 0.003) and with decreased probability of survival (Po0.0001). In a multivariate analysis, pRb2/ p130 status (P ¼ 0.004), tumor stage (P ¼ 0.009) and ploidy status (P ¼ 0.02) were independent predictors of clinical outcome and the risk of dying of disease was increased substantially among patients with loss of pRb2/p130 in tumor cells.
On the basis of these findings, we investigated pRb2/ p130 expression in 102 specimens chosen to represent a spectrum of endometrial changes. We found high expression of pRb2/p130 in proliferative endometrium and in hyperplasia without atypia and downregulation in secretory endometrium, atypical hyperplasia and carcinoma (Susini et al., 2001) , suggesting that Rb2 expression might be estrogen-regulated.
In most studies, Rb expression appears to be the same in normal cervical epithelium, cervical intraepithelial neoplasia and cervical carcinoma (Skomedal et al., 1999) . Some reports (Wrede et al., 1991; Munger et al., 1992) suggest that mutations and LOH of the Rb gene are rare events in cervical cancer and correlate with human papilloma virus (HPV)-negative status, supporting the hypothesis that loss of pRb is required for cervical tumor development and can occur by mutation, LOH or expression of viral proteins capable of complexing and inactivating wild-type cellular proteins. This is the case for HPV16 E7 protein that has recently been shown to bind to pRb2/p130, leading to release of transcriptionally active E2F and progression through cell cycle (Zhang et al., 2006) .
In a study on 49 cases (Chan et al., 1998) , all benign vulvar lesions, 40% of vulvar intraepithelial neoplasia (VIN I-III) and 37% of squamous cell carcinomas expressed pRb. The loss of pRb increased from stage I carcinoma (16.7%) through stage II (26.7%) and III (44.4%), to IV (50%), and was correlated with poor tumor grade (Rolfe et al., 2001) , suggesting that pRb may play an important role in tumor progression. As to pRb2 expression, its decrease from vulvar benign lesions, to VIN and to invasive squamous cell carcinoma, suggests a role in vulvar carcinogenesis, although pRb2 status does not correlate with any clinicopathological parameter (Zamparelli et al., 2001) .
Malignancies of the urinary tract
The role of pRb in bladder cancer is still controversial. In fact, although decreased expression of pRb has been shown to be significantly associated with prognosis (Cordon-Cardo et al., 1992; Logothetis et al., 1992) , a recent study on 173 cases failed to find any correlation between pRb and clinical outcome (Jahnson and Karlsson, 1998) . However, a combined analysis of p53 and pRb in a large series (Cote et al., 1998) showed that cases with altered expression of pRb had significantly higher recurrence (P ¼ 0.0001) and lower survival rates (P ¼ 0.0002) compared to cases with normal pRb expression. Moreover, patients with alteration of both p53 and pRb had significantly increased rates of recurrence (Po0.0001) and decreased survival (Po0.0001) compared to patients with no alterations in either p53 or pRb; patients with alteration in only one of these proteins had intermediate rates of recurrence and survival. Loss of pRb appears to be the main predictor of response to radiation therapy (Pollack et al., 1997) .
In renal cancer, loss of Rb protein does not appear to significantly contribute to malignant transformation. Molecular alterations of the RB gene are infrequent and Rb protein is expressed in the majority of primary and metastatic renal tumors (Walther et al., 1995) .
Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic prostate cancer. Loss of pRb is associated with improved disease-specific survival, both in univariate and multivariate analysis in locally advanced prostate cancer (Chakravarti et al., 2003) . Concerning pRb2, preliminary data suggest that its loss could represent a new parameter to discriminate patients at higher risk for prostate cancer onset (Claudio et al., 2002) .
Sarcomas
It has been reported that over 50% of osteosarcomas have a LOH at the Rb locus, and a higher probability of metastasis has been observed in patients with loss of pRb (Wadayama et al., 1994; Benassi et al., 1999) . The event-free survival rate at 60 months is 100% for patients without LOH, 43% for all patients with Rb LOH and 65% for non-metastatic patients with Rb LOH (Feugeas et al., 1996) .
Prognostic significance of pRb expression in softtissue sarcoma is still unresolved. A preliminary report evaluating the prognostic role of pRB expression in 44 primary and 12 metastatic high-grade human sarcomas by IHC demonstrated that alterations in pRb expression are more commonly associated with high-grade tumors, metastatic lesions and decreased survival rates (Cance et al., 1990) . However, a subsequent report from the same group revealed that pRb alterations were present in both low-and high-grade lesions and pRb was not an independent predictor of long-term outcome (Karpeh et al., 1995) . The now-well-documented phenomenon of late recurrence of soft-tissue sarcoma highlights the importance of long-term follow-up and relatively large sample number in this type of studies. It is likely that the potential prognostic significance of pRb status could be improved by a combined analysis with other biological markers such as p53 and mdm2 (Wurl et al., 1998 (Wurl et al., , 1999 .
Correlation between response to chemotherapy and pRb expression has also been investigated. Lack of functional Rb protein appears to mediate increased resistance to antimetabolites in human sarcoma cell lines (Li et al., 1995) .
Gastrointestinal cancer
In esophageal cancer, Rb mutations have been detected in over 50% of cases (Barrett et al., 1996) and correlate with advanced stage of disease, presence of nodal metastases and decreased survival. Decrease in pRb nuclear staining is also very frequent (43% of cases) and is significantly associated with tumor invasion to the adventitia, presence of lymph node metastasis and poor 3-year survival rate. However, in the multivariate analysis, pRb expression is not an independent prognostic factor in esophageal tumors (Ikeguchi et al., 2000) .
Immunohistochemical staining of Rb gene products together with tumor stage, tumor size, and patient age is an independent prognostic factor of overall survival but not of relapse-free survival in curatively resected gastric cancer (Feakins et al., 2003; Song et al., 2005 ).
There are two major studies investigating the prognostic significance of pRb in colorectal cancer (Poller et al., 1997; Cui et al., 2004) . In the first study (Poller et al., 1997) , pRb immunohistochemical expression was evaluated in 250 primary resectable colorectal carcinomas. Positive nuclear Rb1 staining was observed in 82.8% of cases examined and did not correlate with patient age, sex, site of tumor, tumor size, tumor type (standard or mucinous adenocarcinoma), tumor grade, peritumoral lymphocytic infiltrate, nature of the invasive tumor margin, extramural vascular or lymphatic invasion, lymph node involvement, involvement of peritoneum and Dukes' stage. However, with a mean follow-up of 4.3 years, patients with decreased pRb expression showed a shorter recurrence-free survival and overall survival by univariate analysis. In the second study (Cui et al., 2004) , outcome following resection was worse in patients with abnormalities of pRb and/or p16 expression than in patients with normally expressed pRb and p16 (for pRb, P ¼ 0.0151; for p16, P ¼ 0.0247). Coincident abnormalities of pRb and p16 indicated the worst patient survival (P ¼ 0.0310). Aberrant expression of pRb and p16 independently affected post-resection survival (relative risk ¼ 6.312, Po0.0001; relative risk ¼ 5.994, Po0.0001, respectively).
Relationship between Rb family members and clinical outcome has not been investigated in hepatocellular carcinomas (HCC). However, altered pRB expression appears to be significantly related to poor grade (moderately vs well differentiated, Po0.01; poorly vs moderately differentiated, Po0.001) and advanced stage (Po0.001) (Hui et al., 1999) . Moreover, we recently observed that pRb2/p130 expression in HCC is independent from tumor stage, suggesting its possible role as independent prognostic molecular biomarkers (Claudio et al., 2004) .
Hematological malignancies
Prognostic significance of pRB expression in Hodgkin's disease (HD) has been investigated in a large retrospective analysis of 140 patients collected in 11 different centers (Morente et al., 1997) . In univariate analysis, loss of pRB expression was found to be an adverse prognostic factor affecting capability to achieve complete remission (P ¼ 0.0316). Multivariate analysis confirmed the independent significance of this parameter as predictor of response to chemotherapy (P ¼ 0.0001). Moreover, a statistically significant relation was identified between loss of Rb expression and shorter survival time (P ¼ 0.0380), but this correlation was observed only in univariate analysis and when pRB was studied as a categorized variable (cut off ¼ 20%). Results of this study were not confirmed by a recent report (Guenova et al., 1999) evaluating the immunohistochemical expression of pRb in a series of 44 patients with HD. Methodological factors related to IHC, follow-up and population size might explain different results between the two studies.
In non-Hodgkin's lymphomas (NHL), pRB status is clearly related to histological grade. In high-grade NHL, loss of pRB has been reported in 58% of cases, particularly in centroblastic and Burkitt's lymphomas (BLs) (Weide et al., 1994) . In particular, in BL, mutations disrupting the nuclear localization signal of the Rb-related gene Rb2/p130 have been documented in cell lines and in primary tumors (Cinti et al., 2000) . It seems that BL is composed of a mixture of molecular types with distinct genetic and phenotypic patterns, probably resulting from different pathogenetic mechanisms. In endemic BL, the RB2/p130 gene is mutated in most of the cases, and the protein is restricted to the cytoplasm. In AIDS-related BL, high levels of nuclear expression of the wild-type RB2/p130, p107 and cell proliferation-related proteins are detected, whereas sporadic BLs are mainly characterized by low nuclear values of the wild-type pRb2/p130 and, conversely, high values of p107.
Regarding the prognostic role of pRB expression in NHL, in a study on 141 patients with diffuse large B-cell lymphoma, low levels of pRB expression were significantly associated with shorter survival time both in univariate (Po0.0382) and multivariate analysis (Po0.0020). No correlation was found with progression-free survival and chance to achieve a complete response to therapy (Sanchez et al., 1998) , although a predictive role of pRb for response to radiation has been suggested (Ishii et al., 1997) .
Although it has been reported that deletion of 13q14 is a very common event in multiple myeloma (MM) and is correlated with poor response to standard-dose chemotherapy and shortened survival (Zojer et al., 2000) , mutational inactivation of Rb gene appears to be a rare event in MM.
Lung cancer
Retinoblastoma mutations (truncation by deletion, nonsense mutation or splicing abnormalities), together with loss of the wild-type Rb allele, have been demonstrated in lung cancers (Salgia and Skarin, 1998) . In non-small-cell lung cancer (NSCLC), a strong correlation between pRB alterations and stage has been documented (Goldstein, 2000) . It has been reported that approximately 30% of early-stage NSCLCs show a decreased expression of pRB and that early stage tumors were more likely to have alterations in the pRb pathway than tumors in advanced stage (90 vs 63%, P ¼ 0.002).
Despite these data, correlation between pRb and clinical outcome is still controversial. A preliminary study analysed immunohistochemical expression of pRb in 101 patients with early-stage NSCLC and found that the median survival was 32 months for patients with Rb-positive tumors and 18 months for individuals in whom expression of Rb protein was absent or altered. The difference in overall survival was statistically significant both in univariate (P ¼ 0.007) and in multivariate analysis (P ¼ 0.005). On the basis of these findings, an increasingly high number of molecular biology studies on prognostic role of pRB in NSCLC have been published in the last few years. Unfortunately, all these studies failed to show an independent prognostic value of pRB status in NSCLC (Hommura et al., 1999; Chen et al., 2001) . However, when a combined analysis of pRb and p53 was performed, it was found that pRB/p53 status is a predictive factor of overall survival (Xu et al., 1996) . Individuals with RBÀ/p53( þ ) tumors had a median survival of 12 months, whereas those with RB þ /p53(À) tumors had a median survival of 41 months (P ¼ 0.005 and 0.03, in univariate and multivariate analysis, respectively). High levels of pRb expression seem also to predict chemosensitivity of lung cancer cells to VP-16 and carboplatin (Yamamoto et al., 1998) .
In small-cell lung cancer, loss of pRB is a frequent event (Hensel et al., 1990) , but to date no correlation with clinical outcome has been found.
A previous study suggested that not only pRB but also the other members of this family might contribute to lung carcinogenesis (Helin et al., 1997) . On the basis of these findings, Baldi et al. (1996) investigated immunohistochemical expression of pRb2/p130 in a series of 158 lung cancers and found inverse correlation with histological grade and proliferating cell nuclear antigen (PCNA) expression. The same group confirmed similar results in a larger series of cases Minimo et al., 1999) .
Even though mesotheliomas are among the most aggressive human cancers, alterations of Rb family genes have never been reported in these tumors. However, the presence of SV40-like sequences was observed in 86% of mesotheliomas and SV40 TAg has been proved to bind each of the Rb family proteins. Thus, it is conceivable that the absence of mutations in Rb family members and the unusually high level of expression of these proteins could be compensated by the physical association with SV40 TAg, which should lead to their inactivation.
Head and neck cancer
In nasopharyngeal carcinomas (NPC), alterations of pRb are not a common event (Sun et al., 1993) , whereas mutations of the RB2/p130 gene were detected in 30% of cases, suggesting that genetic changes of RB2/p130 may be involved in the development and/or progression of NPC (Claudio et al., 1994 (Claudio et al., , 2000a . A larger screening of the RB2/p130 gene for mutations in patients with NPC would help to clarify the prognostic significance of these genetic alterations.
In laryngeal carcinomas, alterations in pRB expression are described in 20-30% of cases. Many reports suggest that pRb alteration may be a prognostic indicator in patients with laryngeal carcinoma (Dokiya et al., 1998; Nakahara et al., 2000) . Mizokami et al. (1999) investigated the presence of Rb protein, p53 protein and HPV infection in laryngeal squamous cell carcinoma samples from 79 patients and found that lack of staining for pRb was significantly associated with high histological grade (Po0.05), high T classification (Po0.05), recurrence (Po0.05) and relatively short disease-free interval (Po0.01). Results of this study are in agreement with another study (Sartor et al., 1999) that found that loss of pRb, either partial or complete, was significantly related to lower 5-year survival rate and higher likelihood of lymph node metastasis.
pRb expression levels can also be used as a reliable predictor for recurrence in papillary thyroid tumors (Omura et al., 1997) where low expression of pRb is associated with disease recurrence both in univariate (Po0.001) and in multivariate analysis (Po0.009).
Several studies have shown that alterations in the RB gene may have an important role in oral carcinogenesis (Girod et al., 1998) ; however, prognostic significance of these alterations remains unproved. The role of pRb2/ p130 as prognostic factor seems more significant in oral squamous cell carcinoma. In a recent study, we found a direct correlation between the cytoplasmic expression of pRb2/p130 and tumor grading (Po0.0001) and the presence of metastasis (Po0.001). Additionally, increased cytoplasmic pRb2/p130 expression was significantly correlated with decreased probability of survival (Po0.001). Interestingly, p107 nuclear expression showed a strong direct correlation when compared with the same variables. pRb2/p130 showed the highest percentage of undetectable nuclear levels in the specimens examined and the tightest inverse correlation (Po0.0001) with both histological grading and PCNA expression in malignant salivary tumors (Russo et al., 2005) .
Retinoblastoma family and less frequent sites of malignancies
Central nervous system malignancies such as astrocytomas and glioblastomas are not exempted from pRb alterations. All the published studies documented frequent alterations of the Rb pathway in gliomas, but prognostic significance of these alterations remains controversial (Puduvalli et al., 2000) .
We recently evaluated the prognostic role of all three Rb family members in 55 patients with choroidal melanoma (Massaro-Giordano et al., 1999) . pRb was expressed at a low to undetectable level in all of the examined specimens, whereas, unexpectedly, p107 and pRb2/p130 were always expressed at different levels. No correlation with clinical outcome was found for Rb/ p105 and p107, whereas pRb2/p130 was shown to be an independent prognostic factor correlating positively with patient survival in univariate (P ¼ 0.02) and multivariate analysis (P ¼ 0.0060).
Conclusions
Based on considerable progress made towards gaining an understanding of their prognostic/predictive role in human cancer, it is clear that Rb family members might enter soon in the clinic as bona fide markers for treatment decision. Meanwhile, implementation of our knowledge of the molecular pathways through which Rb family members are involved in different types of tumors will lead to novel therapeutic approaches.
There are two ways to implement new therapeutic strategies: one is represented by the pharmacological manipulation of the cyclin-Rbs-E2F pathway. The development of small molecules that specifically inhibit certain cyclin/CDK complexes or that could affect E2F-dependent transcription, as well as peptides that can mimic the functional regions of Rb proteins inactivated in specific tumors, are currently under investigation.
The second attractive but difficult way is represented by the use of gene therapy to restore the function of individual components of Rb pathways. Data mentioned above provide the necessary experimental basis for considering pRb and pRb2/p130 as realistic bullets against selected cancer. Our and other groups provided several data suggesting that retroviral-mediated delivery of wild-type pRb2/p130 in human cancers can revert the malignant phenotype (Claudio et al., 2000b) . However, moving from preclinical animal models to successful human trials is a daunting task even with the great promise that gene transfer encompasses.
Abbreviations IHC, immunohistochemistry; LOH, loss of heterozygosity.
